EUCTR2011-001288-32-IT进行中（未招募）不适用
A Pilot Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in refractory ER-positive metastatic breast cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Signed, informed consent 2.Histologically or cytologically confirmed ER positive breast cancer refractory to standard therapy or for which no standard therapy exists 3.Recovered from all acute adverse effects of prior therapies (excluding alopecia and grade 1 neuropathy) 4.Adequate bone marrow, hepatic and renal function including the following a.Hb = 9.0 g/dL, absolute neutrophil count = 1.5 x 109/L, platelets =100 x 109/L b.Total bilirubin = 1.5 x upper normal limit, excluding cases where elevated bilirubin can be attributed to Gilberts Syndrome c.AST (SGOT), ALT (SGPT) = 2.5 x upper normal limit (or 5x UNL in the presence of liver metastases) d.Creatinine = 1.5 x upper normal limit 5.Age = 18 years 6.Performance status (PS) = 2 (ECOG scale) 7.Estimated life expectancy greater than 3 months 8.Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include IUD, oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 13
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1.Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to trial entry (or a longer period depending on the defined characteristics of the agents used e.g. 6 weeks for mitomycin or nitrosourea, 3 months for antibodies). In patients with progressive disease, bisphosphonates for bone disease and corticosteroids are permitted provided the dose does not change during the trial 2.Patients with a prior allogeneic haematopoietic stem cell transplant 3.Co-existing active infection or serious concurrent illness 4.Patients with significant cardiovascular disease as defined by: a.LVEF below the normal range at the study centre b.Uncontrolled hypertension c.A history of QTc abnormalities or with a mean QTc interval >450 msec at screening 5.Any medical or other condition that in the Investigator’s opinion renders the patient unsuitable for this study due to unacceptable risk 6.Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies 7.Gastrointestinal disorders that may interfere with absorption of the study drug. 8.Patients with known brain tumours or metastases should be excluded from this clinical trial because of their poor prognosis 9.More than 6 prior chemotherapy regimens 10.Patients requiring palliative radiotherapy within the last 4 weeks prior to study entry 11.Uncontrolled hypercalcaemia (>CTCAE v3 grade I) 12.Pregnant or breast-feeding women
研究者
相似试验
进行中（未招募）
不适用
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-ATIntercept Pharmaceuticals Inc78
进行中（未招募）
不适用
An Early Stage Study to Evaluate the Safety, Tolerability and Efficacy of the Medicinal Product Obeticholic Acid for the Treatment of Portal Hypertension, a liver disease.EUCTR2010-023241-29-GBIntercept Pharmaceuticals Inc78
进行中（未招募）
1 期
Pilot Study Of Obeticholic Acid In Portal HypertensioPortal Hypertension in Patients with CirrhosisMedDRA version: 14.1Level: PTClassification code 10036200Term: Portal hypertensionSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2010-023241-29-BEIntercept Pharmaceuticals Inc78
进行中（未招募）
1 期
A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.Patients with acute mieloyd leukemia (AML)MedDRA version: 20.1Level: LLTClassification code 10024349Term: Leukemia myeloidSystem Organ Class: 100000004864EUCTR2018-000482-36-ESOryzon Genomics S. A.30
进行中（未招募）
1 期
Study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancerEUCTR2018-000469-35-ESOryzon Genomics S. A.33